Pay in 4 interest-free payments of $7.25 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Ascendis Pharma A/S granted Novo Nordisk A/S exclusive global rights to its TransCon technology for the development, manufacturing, and commercialisation of Novo Nordisk products aimed at metabolic diseases, including obesity and type 2 diabetes, along with select cardiovascular applications
Levocarnitine is indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency, and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis
(3) Surface Chemistry: The surface chemistry of MPs plays a critical role in their biological affinity and immune response
Safety and tips Label Warning: For healthy adults 18 years and older
US$ 27.45
US$ 21.27
US$ 26.11
